. 2022 Sep 30;2022:3245663. doi: 10.1155/2022/3245663

Table 1.

Features of the included studies.

Study ID	Sample size	Age	Treatment versus control	Duration of treatment (months)	Outcomes
Chen [23] China	T: 47	T: 28.43 ± 3.83	T: ban-xia-xie-xin-tang, decocted.	3	BMI, WHR, HOMA-IR, FPG, FINS, TC, TG, LDL-c, HDL-c
Chen [23] China	C: 15	C: 27.27 ± 5.75	C: metformin, 500 mg, po, tid	3	BMI, WHR, HOMA-IR, FPG, FINS, TC, TG, LDL-c, HDL-c

Fang et al. [25] China	T: 45	T:25.41 ± 3.48	T: wen-shen-tiao-jing-tang, decocted.	2	BMI, HOMA-IR, FPG, 2hFPG, FINS, 2hINS, TC, TG, HDL-c, LDL-c
Fang et al. [25] China	C: 45	C:25.32 ± 3.37	C: metformin, 500 mg, po, bid.	2	BMI, HOMA-IR, FPG, 2hFPG, FINS, 2hINS, TC, TG, HDL-c, LDL-c

Hong et al. [22] China	T: 23	T: 24.3 ± 5.8	T: jian-pi-qu-tan-tong-luo-tang, decocted.	3	BMI, WHR, HOMA-IR, FPG, FINS, TC, TG, HDL-c, LDL-c
Hong et al. [22] China	C: 22	C: 25.1 ± 6.2	C: metformin, 500 mg, po, tid.	3	BMI, WHR, HOMA-IR, FPG, FINS, TC, TG, HDL-c, LDL-c

Li [24] China	T: 45	T: 25.33 ± 3.97	T: wu-ji-san, powdered medicine.	3	BMI, WHR, FPG, 2hFBG, FINS, 2hFINS, TC, TG, HDL-C
Li [24] China	C: 45	C: 25.33 ± 4.32	C: metformin, 500 mg, po, tid.	3	BMI, WHR, FPG, 2hFBG, FINS, 2hFINS, TC, TG, HDL-C

Liang et al. [31] China	T: 48	24.69 ± 3.55	T: HYKT (Heyan Kuntai capsule)	6	BMI, WHR, HOMA-IR, FPG, 2hFBG, FINS, 2hFINS, TC, TG, HDL-C, LDL-c
Liang et al. [31] China	C: 47	24.69 ± 3.55	C: placebo tid, 4 capsules each time.	6

Liang [28] China	T: 25	T: 23.20 ± 3.73	T: zi-shen-qing-re-li-shi-hua-yu-fang (granules).	3	HOMA-IR, FPG, FINS, 2hFPG,2hINS, TC, TG, HDL-C, LDL-C
Liang [28] China	C: 25	C: 24.20 ± 3.08	C: placebo granules bid, 1 bag each time.	3	HOMA-IR, FPG, FINS, 2hFPG,2hINS, TC, TG, HDL-C, LDL-C

Luo [30] China	T: 19	T: 23.1 ± 5.7	T: bu-shen-hua-tan-qu-yu-fang, decocted.	6	BMI, FPG, FINS, T C, TG, HDL-C, LDL-C
Luo [30] China	C: 16	C: 24.1 ± 4.3	C: metformin, 500 mg, po, qd.	6	BMI, FPG, FINS, T C, TG, HDL-C, LDL-C

Mahdie [29] Iran	T: 29	T: 28.62 ± 5.74	T: cinnamon powder capsules	3	BMI, HOMA-IR, FPG, FINS, 2hFPG, TC, TG, LDL-C, HDL-C
Mahdie [29] Iran	C: 30	C: 26.53 ± 6.35	C: placebo 500 mg, po, tid.	3	BMI, HOMA-IR, FPG, FINS, 2hFPG, TC, TG, LDL-C, HDL-C

Mehri [32] Iran	T: 24	T: 28.6 ± 4.7	T: curcumin	3	BMI, HOMA-IR, FPG, FINS, TC, TG, LDL-C, HDL-C
Mehri [32] Iran	C: 36	C: 27.2 ± 3.4	C: placebo 500 mg/day	3	BMI, HOMA-IR, FPG, FINS, TC, TG, LDL-C, HDL-C

Wang et al. [20] China	T: 40	29.43 ± 4.35	T: cang-fu-dao-tan-tang modified, decocted.	3	BMI, HOMA-IR, FPG, FINS, TC, TG, HDL-C, LDL-C
Wang et al. [20] China	C: 35	29.43 ± 4.35	C: metformin, 500 mg, po, tid.	3	BMI, HOMA-IR, FPG, FINS, TC, TG, HDL-C, LDL-C

Zhao et al. [27] China	T: 36	18～35	T: yang-yin-yi-qi-huo-xue-fang, decocted.	3	BMI, HOMA-IR, FPG, FINS, TC, HDL-C, LDL- C
Zhao et al. [27] China	C: 26	18～35	C: metformin, 500 mg, po, tid.	3	BMI, HOMA-IR, FPG, FINS, TC, HDL-C, LDL- C

Zhao et al. [26] China	T: 30	T: 23.2 ± 3.1	T: yang-yin-yi-qi-huo-xue-fang, decocted.	6	BMI, HOMA-IR, FPG, FINS, TC, TG, HDL-C, LDL-C
Zhao et al. [26] China	C: 22	C: 24.1 ± 2.9	C: metformin, 500 mg, po, tid.	6	BMI, HOMA-IR, FPG, FINS, TC, TG, HDL-C, LDL-C

Zheng et al. [21] China	T: 26	T: 27.02 ± 4.98	T: duo-nang-yin, decoction.	6	BMI, WHR, FPG, FINS, TC, TG, HDL-C, LDL-C
Zheng et al. [21] China	C: 24	C: 27.45 ± 4.67	C: metformin, 500 mg, po, tid.	6	BMI, WHR, FPG, FINS, TC, TG, HDL-C, LDL-C

T: treatment; C: control; po: peros; qd: quaque die; bid: bis in die; tid: ter in die; BMI: body mass index; WHR: waist-to-hip ratio; HOMA-IR: homeostasis model assessment of insulin resistance; FPG: fasting plasma glucose; 2hFPG: 2 h fasting plasma glucose; FINS: fasting insulin; 2hFINS: 2 h fasting insulin; TC: serum total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.